Zobrazeno 1 - 4
of 4
pro vyhledávání: '"I. V. Tsimafeyeu"'
Autor:
M. I. Volkova, A. S. Olshanskaya, I. V. Tsimafeyeu, N. L. Vashakmadze, Yu. A. Khochenkova, E. Sh. Solomko, S. A. Ashuba, D. A. Khochenkov, V. B. Matveev
Publikováno v:
Onkourologiâ, Vol 16, Iss 1, Pp 17-26 (2020)
Objective: to assess the expression and prognostic value of vascular endothelial growth factor A (VEGF-A), fibroblast growth factor 2 (FGF-2) and their receptors VEGFR-1, -2; FGFR-1, -2, as well as platelet-derived growth factor receptors (PDGFR-α,
Autor:
S. Z. Safina, S. A. Varlamov, A. V. Snegovoy, I. S. Varlamov, L. I. Gurina, L. V. Manzuk, I. V. Tsimafeyeu
Publikováno v:
Onkourologiâ, Vol 13, Iss 4, Pp 40-44 (2018)
Background. In a CRAD001LRU02T study of everolimus for metastatic renal cell carcinoma patients previously treated with bevacizumab ± interferon, median overall survival (OS) was 17.4 months (95 % confidence interval 13.5–21.3 month).Objective of
Autor:
I V, Tsimafeyeu
Publikováno v:
Voprosy onkologii. 62(6)
Sunitinib is one of first targeted agents and tyrosine kinase inhibitors of vascular endothelial growth factor receptor (VEGFR) that approved for therapy of metastatic renal cell carcinoma. -Moreover it is among the first compounds in oncology regist
Autor:
I. V. Tsimafeyeu
Publikováno v:
Onkourologiâ, Vol 11, Iss 4, Pp 24-33 (2015)
Non-clear cell renal cell carcinoma has various histologic subtypes. Tumor biology plays significant role in the disease development. However, despite the one surgical approach both to clear cell and non-clear cell renal carcinoma, patients’ outcom